Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.

• Revenue in USD (TTM)0.00
• Net income in USD-40.33m
• Incorporated2004
• Employees20.00

• Location
  Eledon Pharmaceuticals Inc19900 Macarthur Blvd Ste 550IRVINE 92612-8426United StatesUSA
• Phone+1 (949) 238-8090
• Fax+1 (302) 655-5049
• Websitehttps://eledon.com/